ShareValue scores for 214390.KO: Valuation 50, Quality 38, Growth 64, Health 34.

214390.KO
KRX

Kyongbo Pharmaceutical Co Ltd

₩5,240.00(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

3% to 17%
Valuation
50
Fair Value
Price vs Value
Quality
38
Weak
Business Strength
Growth
64
Moderate
Revenue & Earnings
Health
34
Stressed
Financial Stability
Momentum
41
Neutral
Price Trend

Company Details

About

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026